Insulin sensitivity patterns across the menstrual cycle in women with type 1 diabetes
Official title: Trajectories in Insulin Sensitivity Across Menstrual Cycles in Women With Type 1 Diabetes
Run by DCB Research AG · NCT06282055 · Data updated 2026-11-12
This project will use data from your automated insulin delivery system, glucose records, nutrition logs, and menstrual cycle notes to see if insulin needs and glucose patterns change across menstrual cycles in women with type 1 diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | Women only |
| Enrollment | 350 (estimated) |
| Sponsor | DCB Research AG Academic / other |
| Locations | 1 site (Bern) |
| Status | Recruiting |
| Started | November 20, 2025 |
| Main results expected | September 15, 2027 |
| Study ends | September 15, 2027 |
| Registry record updated | December 3, 2025 |
| Trial ID | NCT06282055 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18 to 40 with type 1 diabetes or LADA for at least one year, regular menstrual cycles, and at least six months of automated insulin delivery system use are ideal candidates.
✕Probably not a fit
People who are pregnant or recently postpartum, breastfeeding, using regular systemic hormonal medications, diagnosed with PCOS, have irregular cycles, or are not using an automated insulin delivery system are unlikely to benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will collect standardized longitudinal data on insulin dosing, continuous glucose metrics, nutritional intake, and menstrual timing in women with type 1 diabetes who use automated insulin delivery systems. Participants will provide device downloads and cycle logs across multiple consecutive menstrual cycles to capture within-person changes. Researchers will analyze trajectories of insulin sensitivity and glycaemic variability to identify common pattern categories. The aim is to link menstrual cycle phases and characteristics with predictable changes in insulin requirements.
Why it matters
Potential benefit: If successful, the findings could help patients and clinicians personalize insulin dosing across the menstrual cycle to reduce episodes of high or low blood glucose.
How similar studies have gone: Previous studies indicate menstrual cycle phases can affect insulin sensitivity and glucose variability, but few have used continuous automated insulin delivery data to define trajectory categories, so this approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Female sex * Between 18 and 40 years at inclusion * Menarche at least one year prior to study inclusion * Regular menstrual cycle (at least one menstrual cycle in the last 40 days) * Average menstrual cycle length between 21 and 38 days * Difference in length between consecutive menstrual cycles of at most 7 days * Living with type 1 diabetes or latent autoimmune diabetes in adults (LADA) for at least one year * Actively using an AID system for their diabetes management at least six months prior to study inclusion Exclusion criteria: * Regular hormonal intake (e.g. corticosteroids), except: insulin, stable thyroid substitution, and hormonal contraception * Pregnancy until two months postpartum (ongoing or planned) * Current breastfeeding (including pumping), as well as two months following complete cessation of breastfeeding and pumping * Known Polycystic Ovary Syndrome (PCOS) * Intake of glucocorticoid medication, agents affecting gastric emptying, oral anti-diabetic agents (Metformin) or SGLT-2 inhibitors or GLP-1-analogs * Individuals with work patterns involving frequent shifts between night and day work (e.g., alternating night and day shifts on a weekly or similar basis). * Participation in an interventional study within two months preceding and during the present study
Where it's running
-
DCB Research AG
Bern, Switzerland Recruiting
Study contacts
- Study coordinator: Stefanie Hossmann, MSc
- Email: stefanie.hossmann@dcberne.com
- Phone: +41794217376
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
-
Tirzepatide for type 1 diabetes patients who are overweight or obese
This study tests whether tirzepatide can affect stomach emptying in adults with type 1 diabetes and overweight or obesity.
-
Oral insulin vs. subcutaneous insulin in adults with type 1 diabetes
This study tests an oral insulin tablet (SCD0503) against subcutaneous insulin and placebo to see how it behaves in the blood and helps control blood sugar in adults with type 1 diabetes.
-
Genetic risk score and progression to insulin in type 1 diabetes
This study tests whether a genetic risk score can predict which people with type 1 diabetes will need insulin progression over three years.
-
Home-based use of an advanced hybrid closed-loop insulin pump with telemonitoring for adults with type 1 diabetes
This study tests whether starting an advanced hybrid closed-loop insulin pump at home, with online education and telemonitoring, is feasible and safe for adults with type 1 diabetes.
-
Diabetes multimorbidity and a voice diary app to help self-manage
This study tests whether the Fabla-diabetesMM audio diary app is feasible and helpful for older adults with type 1 or type 2 diabetes who also have additional chronic conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.